 BERWYN, Pa.--BUSINESS WIRE-- pharma--Virpax Pharmaceuticals, Inc. Virpax or the Company NASDAQ:VRPX, today announced its financial results for the quarter ended March 31, 2021, and other recent developments. We successfully completed our initial public offering IPO of 1,800,000 shares of our common stock in mid-February and immediately began our IND enabling studies for EpoladermTM and EnveltaTM, so that we can meet with the FDA and initiate first-in-human trials. Additionally, we recently r 